Ivabradine

Drug Profile

Ivabradine

Alternative Names: AMG-998; Coralan; Coraxan; Corlanor; Corlentor; Ivabradine hydrochloride; LANCORA; ONO-1162; Procoralan; S-16257; S-16257-2; S-57

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Servier
  • Developer Amgen; Ono Pharmaceutical; Servier
  • Class Benzazepines; Bradycardic agents; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris; Chronic heart failure
  • Phase III Coronary artery disease

Most Recent Events

  • 10 Jan 2017 Registered for Chronic heart failure in Canada (PO)
  • 08 Nov 2016 Launched for Chronic heart failure in China (PO) before October 2016 (ISRCTN11703380)
  • 29 Feb 2016 Institut de Recherches Internationales Servier completes the EDIFY trial in Chronic heart failure in United Kingdom, Hungary, Portugal, Italy, Germany, Belgium, Spain, Czech, Austria, Slovenia, Netherlands (EudraCT2012-002742-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top